These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17705569)

  • 41. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
    Kwon MY; Cho HN; Koo DH; Lee YG; Oh S; Lee SS
    Korean J Intern Med; 2018 May; 33(3):577-584. PubMed ID: 28111431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain.
    Kaasa S; Moksnes K; Nolte T; Lefebvre-Kuntz D; Popper L; Kress HG
    J Opioid Manag; 2010; 6(1):17-26. PubMed ID: 20297611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.
    Sathyan G; Jaskowiak J; Evashenk M; Gupta S
    Clin Pharmacokinet; 2005; 44 Suppl 1():7-15. PubMed ID: 16156111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis.
    Shaiova L; Lapin J; Manco LS; Shasha D; Hu K; Harrison L; Portenoy RK
    Support Care Cancer; 2004 Apr; 12(4):268-73. PubMed ID: 14750002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers.
    Darwish M; Kirby M; Robertson P; Hellriegel E; Jiang JG
    J Clin Pharmacol; 2007 Jan; 47(1):56-63. PubMed ID: 17192502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
    Zeppetella G; Messina J; Xie F; Slatkin NE
    Pain Pract; 2010; 10(4):287-93. PubMed ID: 20230447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
    Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
    J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fentanyl buccal tablet: rapid relief from breakthrough pain.
    Taylor DR
    Expert Opin Pharmacother; 2007 Dec; 8(17):3043-51. PubMed ID: 18001263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial.
    Hui D; Kilgore K; Frisbee-Hume S; Park M; Liu D; Balachandran DD; Bruera E
    J Pain Symptom Manage; 2017 Dec; 54(6):798-805. PubMed ID: 28803087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients.
    Nalamachu SR; Narayana A; Janka L
    Curr Med Res Opin; 2011 Apr; 27(4):751-60. PubMed ID: 21288055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
    Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
    Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
    Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.
    Jandhyala R; Fullarton J
    BMJ Support Palliat Care; 2012 Jun; 2(2):156-62. PubMed ID: 24654058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers.
    Darwish M; Tempero K; Jiang JG; Simonson PG
    Arch Drug Inf; 2008 Sep; 1(2):56-62. PubMed ID: 19915709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
    Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
    Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.
    Freise KJ; Savides MC; Riggs KL; Owens JG; Newbound GC; Clark TP
    J Vet Pharmacol Ther; 2012 Aug; 35 Suppl 2():21-6. PubMed ID: 22731772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.